- Home
- ALZN vs AIDX Comparison
ALZN vs AIDX Comparison
Compare ALZN & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALZN | AIDX |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.7M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ALZN | AIDX |
|---|---|---|
| Price | $1.66 | $0.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | 69.6K | ★ 86.3K |
| Earning Date | 03-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.77 | 34.48 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,045,133.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.71 |
| 52 Week Low | $0.84 | $0.40 |
| 52 Week High | $2.68 | $14.09 |
Technical Indicators
Market Signals| Indicator | ALZN | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 68.02 | 57.79 |
| Support Level | $1.04 | $0.52 |
| Resistance Level | $2.25 | $0.70 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 100.00 | 66.54 |
Price Performance
Historical ComparisonAbout ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.